CYT - Cyteir Therapeutics, Inc. Stock Price, Fair Value and News

$3.010.00 (0.00%)

Market Closed

CYT Stock Valuation Analysis

Valuation

Max Portfolio %

CYT Price Action

CYT RSI Chart

CYT Stock Valuation Analysis

Valuation

Max Portfolio %

CYT Valuation

CYT Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CYT Fundamentals

CYT Earnings

CYT Profitability

CYT Investor Care

Revenue & Growth

About Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

CEO	Dr. Markus F. Renschler M.D.
WEBSITE	https://cyteir.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	46